


World leading gene and cell therapy company

INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2015

27 August 2015



OxfordBioMedica 


Forward-looking statements

This presentation does not constitute an offer to sell or a solicitation of offers to buy Ordinary Shares (the “Securities”). Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, the contents of this presentation have not been formally verified by Oxford BioMedica plc (the “Company”) or any other person. Accordingly, no representation or warranty, expressed or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this presentation, and no reliance should be placed on such information or opinions. Further, the information in this presentation is not complete and may be changed. Neither the Company nor any of its respective members, directors, officers or employees nor any other person accepts any liability whatsoever for any loss howsoever arising from any use of such information or opinions or otherwise arising in connection with this presentation.

This presentation may contain forward-looking statements that reflect the Company's current expectations regarding future events, its liquidity and results of operations and its future working capital requirements. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the success of the Company's development strategies, the successful and timely completion of clinical studies, securing satisfactory licensing agreements for products, the ability of the Company to obtain additional financing for its operations and the market conditions affecting the availability and terms of such financing.


- **Strengthening OXB's position as a world-leading independent gene and cell therapy company**
- **Developments across wholly-owned pipeline:**
 - Encouraging results from RetinoStat® Phase I study
 - Promising follow-up data from ProSavin® Phase I/II study. OXB-102 Phase I/II clinical trial on schedule to begin in 2016
 - EncorStat® being prepared for Phase I/II study
 - Highly attractive CAR-T 5T4 research programme progressing well
- **Novartis contract on track:**
 - Multiple CTL019 lentiviral vector batches manufactured for Novartis during first half of year
 - Novartis-led global CTL019 trial ongoing, using OXB-manufactured vector
 - Process development activities well underway and on target
- **Manufacturing capacity expansion:**
 - Harrow House expansion due to complete by end-2015
 - New Yarnton facility construction nearing completion
 - Windrush Court laboratory upgrade on track

Value Creating Business Model




OXB is a World-leader in Lentiviral Vectors


Several significant advantages over AAV



Larger therapeutic payloads – size of genes



No pre-existing immune response



Permanent modification of dividing cells such as T-cells or stem cells – sustained expression after single administration

Provides potential for “one shot” treatment giving long-term or permanent efficacy


OXB active in both *in vivo* and *ex vivo* therapies

in vivo


ex vivo

For OXB's wholly-owned portfolio products...


ProSavin® /OXB-102
(Parkinson's disease)




RetinoStat®
(Wet AMD)



EncorStat®
(Corneal graft rejection)



CAR-T 5T4
(Cancer multiple)




...and for OXB's partnerships




OXB's *in vivo* approach validated by Sanofi in both Stargardt's disease and Usher's syndrome



Lentiviral vector manufacturing for CTL019



Why Novartis Chose OXB: Fully Integrated Expertise OxfordBioMedica




NOVARTIS

Product portfolio

OxfordBioMedica 



Broad Portfolio of Pipeline Products

Field	Product	Indication	Research/Pre-Clinical	Phase I	Phase I/II	Phase II	Next inflection / Comment	Est. date
LentiVector® platform technology								
OPHTHALMOLOGY	RetinoStat®	Wet AMD	Phase I concluded (primary end point met) → Next phase being evaluated				TBD	TBD
	EncorStat®	Corneal graft rejection	Pre-clinical complete	Phase I/II prep'n			FPI Phase I/II	2016
	Glaucoma-GT	Chronic glaucoma					End pre-clinical	2016
CNS	ProSavin® OXB-102	Parkinson's disease	ProSavin® Phase I/II concluded				FPI OXB-102 Phase I/II	2016
	MoNuDin®	Motor neuron disease/ALS	OXB-102 Phase I/II preparation				End pre-clinical	2016
5T4 TECHNOLOGY								
ONCOLOGY	TroVax®	Cancer (multiple)	Phase I, Phase I/II and Phase II investigator-led studies underway				End Phase II	2015/16
	CAR-T 5T4	Cancer (multiple)					End pre-clinical	2016
LentiVector® platform technology								
OPHTHALMOLOGY	SAR 422459	Stargardt disease	Phase I/II ongoing			Undisclosed development milestones and royalties	Peak sales: \$500m	Launch 2021
	 SAR 421869	Usher syndrome	Phase I/II ongoing				Peak sales: \$90m	

Proprietary

Out-Licensed

Phase I summary (ARVO, May 2015)

- Enrolled patients with highly fibrotic retinas with poor anti-VEGF response following prior responsive history
- Primary end points (safety and tolerability) met
- Gene expression dose-dependent and stable over at least 12 months
- Signs of clinical benefit, with visual acuity stabilisation and reduction in vascular leakage
- Developing plans for next stage

3 year data (AANS, May 2015)

- Significant improvement in patients' UPDRS Part III motor scores while off medication had been observed in Phase I/II study at 6 and 12 months (published in The Lancet, January 2014)
- This has been sustained in the majority of patients for up to 3 years in the long-term follow up
- Encouraging support for the continued development of OXB-102, an enhanced construct of ProSavin®

TroVax[®]

- Phase I, I/II and II investigator-led studies currently ongoing
- Encouraging interim data from the colorectal cancer study presented at The Cancer Vaccine Institute's 2nd International Symposium in May 2015

CAR-T 5T4

- CAR-T 5T4 is a combination of OXB's LentiVector[®] and 5T4 platforms
- Targets 5T4, an oncofetal antigen expressed on the surface of most solid tumors
- 2 different CAR-T 5T4 lentiviral based vectors have been manufactured; both transduce human PBMCs
- Encouraging *in vitro* and *in vivo* data



OxfordBioMedica

Financial Summary


- **Substantial step up in the Group's activities clearly reflected in the financial statements**
 - Total income up 14%
 - Revenue of £4.4 million (H1 2014: £4.7 million)
 - Other income of £1.4 million (H1 2014: £0.4 million)
- **Investment in staff and facilities to service increased demand**
 - Research & Development costs of £9.3 million (H1 2014: £6.9 million) in line with expectations
 - Headcount increased from 134 (December 2014) to 192 (June 2015)
- **Net loss of £6.1 million (H1 2014: £4.9 million)**
- **Capital expenditure £4.6 million (H1 2014: £0.1 million)**
- **Net cash of £15.1 million (31 December 2014: £14.2 million)**
- **\$50 million loan facility secured - \$25 million drawn down May 2015**

Revenue and Other Income

Income split between Revenue and Other Operating Income driven by accounting standards

	2015	2014
Revenue	Batch manufacturing 3 rd party process development Licence income	Batch manufacturing 3 rd party process development Licence income
Other Income	Grants “Collaborative” process development*	Grants


Revenues + Other Income (£m)




NB
 1) H2 2014 excludes £4.8m Novartis up-fronts
 2) During H1 2015 a batch of OXB own material was manufactured, reducing potential revenue

* Collaborative process development – OXB owns or shares arising IP

R&D - £m



Average Headcount



Capacity expansion and capital expenditure

H1 2015 Capital expenditure

Construction/freehold improvement	£3.9m
Equipment	£0.7m

Windrush Court
Corporate Headquarters &
Laboratories
71,955 sq. ft (6,684 sq m)



Harrow House
(GMP1/GMP2/GMP3)
Fill & Finish
API manufacturing facility
32,000 sq.ft (2,980 sq.m)



Yarnton
(GMP4)
API manufacturing facility
18,300 sq. ft (1,700 sq. m)
(Leased)

- \$50m facility for capacity expansion, pipeline advancement, product acquisitions
- \$25m drawn immediately, repaid £3m AMSCI loan
- 5 tranches of \$5m still available (i.e \$25m)
- Repayable May 2022, but may be repaid at any time subject to early repayment fees
- Interest rate 9.5% + 1% or 3 month LIBOR if greater

H2 2015

- Significant increase in Novartis revenues
 - ~ 30%-40% more batch manufacture
 - No OXB own product scheduled for H2 2015
 - Yarnton should come on line towards end 2015
 - Potential for milestone payments totalling up to £5m
- Cost growth flattening off
 - Most staff now in place for full operation of Harrow House (GMP1 and GMP2) and Yarnton (GMP4) and supporting services
- Substantial increase in capital expenditure
 - Yarnton completion around end Q3
 - Harrow House GMP2 completion around end 2015
 - Windrush Court laboratories completion around end 2015/early 2016

2016

- Almost double manufacturing capacity (cf 2015)
- Further Novartis milestones
- Potential new OXB Solutions business – process development and manufacturing with options for further capacity expansion at Harrow House if demand is clear



OxfordBioMedica

Summary

Near Term Catalysts for 2015/16

- RetinoStat[®] development pathway and indication decision – advances into Phase II
- Further IP licences/manufacturing/process development contracts
- Identification of new product development candidates
- TroVax[®] Phase II studies – initial results
- FPI OXB-102 clinical programme
- FPI EncorStat[®] clinical programme
- SAR 422459 / SAR 421869 development milestones
- Glaucoma-GT, CAR-T 5T4 and MoNuDin[®] pre-clinical data

OXB in Summary

Oxford BioMedica is a leading gene and cell therapy biotechnology company with strengths in product development, manufacturing and IP



1

- Innovative portfolio of unencumbered gene therapy assets

2

- Validating and revenue generating partnerships

3

- Established, GMP-qualified, manufacturing facilities

4

- Solid financial position. Multiple catalysts on the horizon

5

- Experienced team with proven track record of execution

Contact Us

Oxford BioMedica plc
Windrush Court
Transport Way
Oxford
OX4 6LT

John Dawson, CEO
Tim Watts, CFO

www.oxfordbiomedica.co.uk
enquiries@oxfordbiomedica.co.uk

Tel: +44 (0) 1865 783 000